secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001326732-25-000063
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor appoints Raymond Deshaies, Ph.D. to board of directors
-------------------------------------------------------------

- Dr. Deshaies is a former SVP of global research at Amgen with 25+ years in biotech.
- Received initial option grant with $550,000 Black-Scholes value; vests over 3 years.
- Also receives $50,000 annual cash retainer; standard indemnification agreement.
- Deshaies co-founded Proteolix (discovered carfilzomib/KYPROLIS) and Cleave Biosciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000063/0001326732-25-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000063/xncr-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001326732-25-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer